批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
>>>原始批准或临时批准<<<
| 审批日期 | 提交号 | 审批结论 | 提交分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
| 2011/05/27 |
ORIG-1(原始申请) |
Approval |
Type 1 - New Molecular Entity |
PRIORITY
;Orphan
|
|
|
>>>补充申请<<<
| 审批日期 | 提交号 | 审批结论 | 补充类别或审批类型 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
| 2020/05/28 |
SUPPL-13(补充) |
Approval |
Labeling-Container/Carton Labels,Labeling-Package Insert |
STANDARD
;Orphan
|
|
|
| 2020/01/24 |
SUPPL-12(补充) |
Approval |
Efficacy-New Patient Population |
PRIORITY
;Orphan
|
|
|
| 2019/04/05 |
SUPPL-11(补充) |
Approval |
Labeling-Patient Package Insert,Labeling-Package Insert |
STANDARD
|
|
|
| 2019/03/15 |
SUPPL-10(补充) |
Approval |
Labeling-Package Insert,Labeling-Package Insert |
STANDARD
|
|
|
| 2015/02/24 |
SUPPL-9(补充) |
Approval |
Efficacy-Pediatric |
PRIORITY
|
|
|
| 2013/11/18 |
SUPPL-7(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
| 2013/06/06 |
SUPPL-6(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
| 2013/04/04 |
SUPPL-4(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
Please see www.fda.gov/STIC for labeling requirements on susceptibility test interpretive criteria for systemic antibacterial and antifungal drugs. |
| 2013/02/21 |
SUPPL-5(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
| 2012/12/19 |
SUPPL-3(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
与本品治疗等效的药品
>>>活性成分:FIDAXOMICIN; 剂型/给药途径:TABLET;ORAL; 规格:200MG; 治疗等效代码:AB<<<
| 申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
| 201699 |
001 |
NDA |
DIFICID |
FIDAXOMICIN |
TABLET;ORAL |
200MG |
Prescription |
Yes |
Yes |
AB |
2011/05/27
|
CUBIST PHARMS LLC |
| 208443 |
001 |
ANDA |
FIDAXOMICIN |
FIDAXOMICIN |
TABLET;ORAL |
200MG |
Prescription |
No |
No |
AB |
2024/01/16
|
ACTAVIS LABS FL |